Arca
Skip to content
Tools
Tools

Pancreatitis

Drug research and approvals for pancreatitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 139 studies of pancreatitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 4 drug trials for it since 2013, FDA has 0 approved and 5 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 139
  • Trials authorized in Canada: 4
  • FDA orphan approvals: 0
  • EU medicines: 1

Recruiting now

Newest posted first, of 139 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 1

Phase 3 6

Phase 2 12

Phase 1 or earlier 9

How its trials ended

721 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 137 whose ending is known, 34% met their primary endpoint, 13% missed it and 53% stopped early.

  • Completed, result not reported26737%
  • Ongoing17524%
  • Status unknown14220%
  • Met its primary endpoint477%
  • Stopped: other or unclear426%
  • Missed its primary endpoint182%
  • Stopped: enrollment or feasibility132%
  • Stopped: sponsor or business decision71%
  • Stopped: lack of efficacy61%
  • Stopped: safety3<1%
  • Stopped: funding1<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
May 27, 2026Double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of plozasiran in adults with severe hypertriglyceridemia at high risk of…Plozasiran (ADS-005)Arrowhead Pharmaceuticals, Inc.Ongoing
Jun 4, 2025A phase 2a, multi-center, randomized, open-label study to evaluate the safety & efficacy of a single dose of RABI-767 admin by endoscopic ultrasound-guided…RABI-767Panafina, Inc.Ongoing
Jun 22, 2021Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of evinacumab in patients with severe hypcrtriglyceridemia for the…REGN1500RegeneronClosed
Jan 22, 2014Timing of indomethacin administration for the prevention of post-ercp pancreatitisIndomethacinGovernors of The University of AlbertaPending

FDA orphan designations

Approved first, then open designations, newest first
Oct 22, 2025Camostat mesilateTreatment of chronic pancreatitisPangenix Pharma LimitedDesignated
Jul 1, 2024ProglumideTreatment of chronic pancreatitisCCKr Therapeutics. Inc.Designated
Sep 9, 2020ProglumideTreatment of Chronic PancreatitisRNR BioMedical Inc.Designated
Sep 5, 2019PEGylated recombinant human tumor necrosis factor-related…Treatment of chronic pancreatitis.Theraly Fibrosis, Inc.Designated
May 18, 2011CamostatTreatment of chronic pancreatitisNIXS CorporationDesignated

Medicines authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
May 3, 2019WaylivraVolanesorsen · orphanAkcea Therapeutics Ireland LimitedEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.